Cambridge Investment Research Advisors
XERS icon

Cambridge Investment Research Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$320K Buy
40,424
+5,750
+17% +$36.7K ﹤0.01% 3153
2026
Q1 		$201K Buy
34,674
+32
+0.1% +$212 ﹤0.01% 3676
2025
Q4 		$272K Hold
34,642
– – ﹤0.01% 3298
2025
Q3 		$282K Hold
34,642
– – ﹤0.01% 3167
2025
Q2 		$162K Buy
34,642
+100
+0.3% +$458 ﹤0.01% 3397
2025
Q1 		$190K Hold
34,542
– – ﹤0.01% 3222
2024
Q4 		$117K Hold
34,542
– – ﹤0.01% 3309
2024
Q3 		$98K Hold
34,542
– – ﹤0.01% 3274
2024
Q2 		$78K Buy
34,542
+500
+1% +$1.01K ﹤0.01% 3183
2024
Q1 		$75K Buy
34,042
+1,872
+6% +$4.84K ﹤0.01% 3179
2023
Q4 		$76K Sell
32,170
-3,500
-10% -$6.46K ﹤0.01% 3064
2023
Q3 		$66K Buy
+35,670
New +$81.7K ﹤0.01% 3014

Other funds holding XERS

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
AL
Aspiriant LLC Los Angeles, California $4.05B AUM 19.01% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Cambridge Investment Research Advisors's XERS Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Xeris Biopharma Holdings (XERS) stake by 17% in Q2 2026, buying an estimated $36.7K and bringing the position to 40,424 shares worth $320K. The position accounts for ﹤0.01% of the portfolio, ranked #3153.

Cambridge Investment Research Advisors first reported a position in XERS in Q3 2023 and has held it in 12 quarters since. 34 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Cambridge Investment Research Advisors held 40,424 shares of Xeris Biopharma Holdings worth $320K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 5,750 Xeris Biopharma Holdings shares in Q2 2026, an estimated $36.7K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3153 holding.
  • Cambridge Investment Research Advisors first reported a position in Xeris Biopharma Holdings in Q3 2023 and has held it in 12 quarters since.
  • 34 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.